权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Analysis of leukocyte adhesion molecule PSGL-1 activation caused by inhibition of vascular endothelial growth factor(VEGF)

抑制血管内皮生长因子(VEGF)引起的白细胞粘附分子PSGL-1活化分析

基本信息

批准号：
22791643
负责人：
NODA Kousuke
金额：
$ 2.5万
依托单位：
Hokkaido University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Young Scientists (B)
财政年份：
2010
资助国家：
日本
起止时间：
2010 至 2011
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791643/
关键词：
VEGF阻害薬白血球ローリング加齢黄斑変性

项目摘要

Age-related macular degeneration(AMD) is a leading cause of visual disturbance among people over age 50 in the developed country. Recently, anti-VEGF antibody or its fragment is used as therapeutic agent for AMD in the clinical setting, and growing evidence have indicated that anti-VEGF therapy may cause the systemic complications related to arterial thromboembolism. In the current study, we hypothesized that leukocyte activation participates in the process of arterial thromboembolism formation caused by anti-VEGF therapy and sought to elucidate the mechanism. Consequently, our data demonstrates that administration of anti-VEGF antibody causes no leukocyte activation ; however, it also indicates the beneficial information to the further evaluation of the mechanism, possible relevance of platelet activation in arterial thromboembolism due to anti-VEGF therapy.

视网膜相关性黄斑变性（AMD）是发达国家50岁以上人群视力障碍的主要原因。近年来，抗VEGF抗体或其片段被用于临床治疗AMD，越来越多的证据表明抗VEGF治疗可能导致与动脉血栓栓塞相关的全身性并发症。在本研究中，我们假设白细胞活化参与了抗VEGF治疗引起的动脉血栓栓塞形成的过程，并试图阐明其机制。因此，我们的数据表明，给予抗VEGF抗体不会引起白细胞活化;然而，这也表明了进一步评价抗VEGF治疗引起的动脉血栓栓塞中血小板活化的机制和可能相关性的有益信息。